
Contents

Contents	vii
Preface	xi
Glossary	xv
1 Introduction to health economic evaluation	1
1.1 Introduction	1
1.2 Health economic evaluation	2
1.2.1 Clinical trials versus decision-analytical models	5
1.3 Cost components	6
1.3.1 Perspective and what costs include	6
1.3.2 Sources and types of cost data	7
1.4 Outcomes	9
1.4.1 Condition specific outcomes	10
1.4.2 Generic outcomes	10
1.4.3 Valuing outcomes	13
1.5 Discounting	17
1.6 Types of economic evaluations	18
1.6.1 Cost-minimisation analysis	18
1.6.2 Cost-benefit analysis	19
1.6.3 Cost-effectiveness analysis	22
1.6.4 Cost-utility analysis	22
1.7 Comparing health interventions	25
1.7.1 The cost-effectiveness plane	27
2 Introduction to Bayesian inference	29
2.1 Introduction	29
2.2 Subjective probability and Bayes theorem	31
2.2.1 Probability as a measure of uncertainty against a standard	31
2.2.2 Fundamental rules of probability	33
2.2.3 Coherence	34
2.2.4 Bayes theorem	36
2.3 Bayesian (parametric) modelling	38
2.3.1 Exchangeability and predictive inference	40
2.3.2 Inference on the posterior distribution	43

2.4	Choosing prior distributions and Bayesian computation . . .	48
2.4.1	Vague priors	49
2.4.2	Conjugate priors	54
2.4.3	Monte Carlo estimation	59
2.4.4	Non conjugate priors	62
2.4.5	Markov Chain Monte Carlo methods	63
2.4.6	MCMC convergence	66
2.4.7	MCMC autocorrelation	68
3	Statistical cost-effectiveness analysis	75
3.1	Introduction	75
3.2	Decision theory and expected utility	76
3.2.1	The problem	76
3.2.2	Decision criterion: maximisation of the expected utility	78
3.3	Decision making in health economics	80
3.3.1	Statistical framework	81
3.3.2	Decision process	83
3.3.3	Choosing a utility function: the net benefit	84
3.3.4	Uncertainty in the decision process	89
3.4	Probabilistic sensitivity analysis to parameter uncertainty	91
3.5	Reporting the results of probabilistic sensitivity analysis	93
3.5.1	Cost-effectiveness acceptability curves	94
3.5.2	The value of information	97
3.5.3	The value of partial information	100
3.6	Probabilistic sensitivity analysis to structural uncertainty	103
3.7	Advanced issues in cost-effectiveness analysis	107
3.7.1	Including a risk aversion parameter in the net benefit	107
3.7.2	Expected value of information for mixed strategies	111
4	Bayesian analysis in practice	115
4.1	Introduction	115
4.2	Software configuration	116
4.3	An example of analysis in JAGS/BUGS	117
4.3.1	Model specification	118
4.3.2	Pre-processing in R	118
4.3.3	Launching JAGS from R	121
4.3.4	Checking convergence and post-processing in R	122
4.4	Logical nodes	127
4.5	For loops and node transformations	129
4.5.1	Blocking to improve convergence	133
4.6	Predictive distributions	135
4.6.1	Predictive distributions as missing values	138
4.7	Modelling the cost-effectiveness of a new chemotherapy drug in R/JAGS	141

<i>Contents</i>	ix
4.7.1 Programming the analysis of the EVPPI	146
4.7.2 Programming probabilistic sensitivity analysis to structural uncertainty	149
5 Health economic evaluation in practice	153
5.1 Introduction	153
5.2 Cost-effectiveness analysis alongside clinical trials	154
5.2.1 Example: RCT of acupuncture for chronic headache in primary care	155
5.2.2 Model description	155
5.2.3 JAGS implementation	157
5.2.4 Cost-effectiveness analysis	159
5.2.5 Alternative specifications of the model	161
5.3 Evidence synthesis and hierarchical models	165
5.3.1 Example: Neuraminidase inhibitors to reduce influenza in healthy adults	169
5.3.2 Model description	171
5.3.3 JAGS implementation	172
5.3.4 Cost-effectiveness analysis	177
5.4 Markov models	178
5.4.1 Example: Markov model for the treatment of asthma	182
5.4.2 Model description	186
5.4.3 JAGS implementation	187
5.4.4 Cost-effectiveness analysis	189
5.4.5 Adding memory to Markov models	193
5.4.6 Indirect estimation of the transition probabilities . .	195
References	199
Index	211